Clinical trial / 2019
Vitamin D supplementation did not lower the incidence of invasive cancer or major cardiovascular events in older US adults.
A randomized, placebo-controlled trial tested vitamin D3 (2000 IU/day) versus placebo for the prevention of cancer and cardiovascular disease over a median follow-up of 5.3 years in 25,871 participants. Vitamin D was not associated with a lower risk of invasive cancer (HR 0.96; 95% CI, 0.88 to 1.06; P=0.47) or major cardiovascular events (HR 0.97; 95% CI, 0.85 to 1.12; P=0.69). Secondary endpoints, including death from cancer (HR 0.83; 95% CI, 0.67 to 1.02) and death from cardiovascular causes (HR 1.11; 95% CI, 0.88 to 1.40), also showed no significant differences, and no excess risks of hypercalcemia or other adverse events were identified.
- Study type
- Randomized, placebo-controlled trial (two-by-two factorial)
- Who was studied
- 25,871 participants (men >=50 y, women >=55 y, including 5,106 black participants) in the US
- What was measured
- Invasive cancer of any type and major cardiovascular events
THE PAPER
Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, VITAL Research Group. N Engl J Med, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.